A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(23 sites)

United States

University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama

Cedars-Sinai Medical Center, Los Angeles, California

University of Chicago Medical Center, Chicago, Illinois

University of Nebraska Medical Center, Omaha, Nebraska

Duke University Hospital, Durham, North Carolina

The Ohio State University Wexner Medical Center, Columbus, Ohio

Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center, Richmond, Virginia

University of Washington Medical Center, Seattle, Washington

Austria

Allgemeines Krankenhaus der Stadt Wien (AKH Wien) - Medizinischer Universitätscampus, Vienna

Belgium

Universitair Ziekenhuis (UZ) Gent, Ghent

Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg, Leuven

Canada

London Health Sciences Centre, London

Czechia

Institut klinicke a experimentalni mediciny (IKEM), Prague

France

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Pellegrin, Bordeaux

Centre Hospitalier Universitaire (CHU) de Grenoble Alpes - Hôpital Michallon, La Tronche

Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil, Toulouse

Germany

Charité - Universitätsmedizin Berlin, Berlin

Universitaetsklinikum Carl Gustav Carus Dresden, Dresden

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Spain

Hospital Del Mar, Barcelona

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Universitario de Bellvitge, Barcelona

Hospital Universitario Miguel Servet, Zaragoza